215 related articles for article (PubMed ID: 19089341)
1. Modulating cGMP to treat lung diseases.
Ghofrani HA; Grimminger F
Handb Exp Pharmacol; 2009; 191(191):469-83. PubMed ID: 19089341
[TBL] [Abstract][Full Text] [Related]
2. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
Castro LR; Schittl J; Fischmeister R
Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
[TBL] [Abstract][Full Text] [Related]
3. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cGMP in heart failure: a new therapeutic paradigm.
Boerrigter G; Lapp H; Burnett JC
Handb Exp Pharmacol; 2009; (191):485-506. PubMed ID: 19089342
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice.
Schmidt EP; Damarla M; Rentsendorj O; Servinsky LE; Zhu B; Moldobaeva A; Gonzalez A; Hassoun PM; Pearse DB
Am J Physiol Lung Cell Mol Physiol; 2008 Dec; 295(6):L1056-65. PubMed ID: 18849438
[TBL] [Abstract][Full Text] [Related]
7. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
Kopra K; Sharina I; Martin E; Härmä H
Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
[TBL] [Abstract][Full Text] [Related]
8. Role of sGC-dependent NO signalling and myocardial infarction risk.
Wobst J; Kessler T; Dang TA; Erdmann J; Schunkert H
J Mol Med (Berl); 2015 Apr; 93(4):383-94. PubMed ID: 25733135
[TBL] [Abstract][Full Text] [Related]
9. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.
Dunkern TR; Feurstein D; Rossi GA; Sabatini F; Hatzelmann A
Eur J Pharmacol; 2007 Oct; 572(1):12-22. PubMed ID: 17659276
[TBL] [Abstract][Full Text] [Related]
11. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes.
Geng Y; Zhou L; Thompson WJ; Lotz M
J Biol Chem; 1998 Oct; 273(42):27484-91. PubMed ID: 9765278
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP.
Wykes V; Bellamy TC; Garthwaite J
J Neurochem; 2002 Oct; 83(1):37-47. PubMed ID: 12358727
[TBL] [Abstract][Full Text] [Related]
13. The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.
Francis SH
Circ Res; 2010 Nov; 107(10):1164-6. PubMed ID: 21071713
[No Abstract] [Full Text] [Related]
14. Structure and regulation of soluble guanylate cyclase.
Derbyshire ER; Marletta MA
Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle.
Hamad AM; Range S; Holland E; Knox AJ
Am J Physiol; 1997 Oct; 273(4):L807-13. PubMed ID: 9357856
[TBL] [Abstract][Full Text] [Related]
16. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
Evgenov OV; Kohane DS; Bloch KD; Stasch JP; Volpato GP; Bellas E; Evgenov NV; Buys ES; Gnoth MJ; Graveline AR; Liu R; Hess DR; Langer R; Zapol WM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1138-45. PubMed ID: 17872487
[TBL] [Abstract][Full Text] [Related]
17. Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.
Mergia E; Stegbauer J
Curr Hypertens Rep; 2016 Apr; 18(5):39. PubMed ID: 27079836
[TBL] [Abstract][Full Text] [Related]
18. High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria.
Wen JF; Cui X; Jin JY; Kim SM; Kim SZ; Kim SH; Lee HS; Cho KW
Circ Res; 2004 Apr; 94(7):936-43. PubMed ID: 14988225
[TBL] [Abstract][Full Text] [Related]
19. Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.
Di Iorio P; Ronci M; Giuliani P; Caciagli F; Ciccarelli R; Caruso V; Beggiato S; Zuccarini M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008687
[TBL] [Abstract][Full Text] [Related]
20. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase.
van Deel ED; Merkus D; van Haperen R; de Waard MC; de Crom R; Duncker DJ
Am J Physiol Heart Circ Physiol; 2007 Aug; 293(2):H1144-53. PubMed ID: 17496213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
